高级检索
当前位置: 首页 > 详情页

Four types of RNA modification writers predict the prognosis of prostate cancer

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Guangzhou Univ Chinese Med, Shenzhen Baoan Tradit Chinese Med Hosp, Dept Androl, Shenzhen, Peoples R China [2]Yunnan Univ Chinese Med, Affiliated Hosp 1, Yunnan Prov Hosp Tradit Chinese Med, Dept Androl, Kunming, Yunnan, Peoples R China [3]Beijing Univ Chinese Med, Xiamen Hosp, Clin Med Coll 8, Xiamen, Peoples R China
出处:
ISSN:

关键词: prognosis prostate cancer RNA modification writers

摘要:
RNA modification is an important part of epigenetic regulation. However, the relationship between RNA modification writers and prostate cancer (PCa) remains unclear. We obtained transcriptome data from The Cancer Genome Atlas; the expression of writers for four RNA modifications (N6-methyladenosine, N1-methyladenosine, alternative polyadenylation and adenosine-to-inosine RNA editing) was altered in PCa tissue when compared with normal tissue. RNA modification writers affect the expression of immune checkpoints. Gene ontology (GO) functional enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses revealed that the RNA modification was related to the cell cycle. Hub genes were screened using machine learning, and a risk score model was established using multivariate Cox analysis. Univariate and multivariate Cox analyses showed that a risk score model based on RNA modification writers could be an independent prognostic factor for PCa. In conclusion, our study showed that RNA modification writers are differentially expressed in PCa and might influence the development of PCa by regulating immune checkpoints and the cell cycle. The risk score model of RNA modification writers is predicted to be an independent prognostic factor for PCa. Thus, RNA modification writers might be used as potential indicators for the clinical diagnosis of PCa.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2022]版:
大类 | 4 区 医学
小类 | 4 区 男科学
最新[2023]版:
大类 | 4 区 医学
小类 | 4 区 男科学
JCR分区:
出版当年[2021]版:
Q3 ANDROLOGY
最新[2023]版:
Q3 ANDROLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者:
第一作者机构: [1]Guangzhou Univ Chinese Med, Shenzhen Baoan Tradit Chinese Med Hosp, Dept Androl, Shenzhen, Peoples R China [2]Yunnan Univ Chinese Med, Affiliated Hosp 1, Yunnan Prov Hosp Tradit Chinese Med, Dept Androl, Kunming, Yunnan, Peoples R China [3]Beijing Univ Chinese Med, Xiamen Hosp, Clin Med Coll 8, Xiamen, Peoples R China
通讯作者:
通讯机构: [2]Yunnan Univ Chinese Med, Affiliated Hosp 1, Yunnan Prov Hosp Tradit Chinese Med, Dept Androl, Kunming, Yunnan, Peoples R China [3]Beijing Univ Chinese Med, Xiamen Hosp, Clin Med Coll 8, Xiamen, Peoples R China [*1]Department of Andrology, Yunnan Provincial Hospital of Traditional Chinese Medicine, Kunming, Yunnan, China. [*2]Xiamen Hospital (The Eighth Clinical Medical College), Beijing University of Chinese Medicine, Xiamen, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:82490 今日访问量:0 总访问量:681 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 云南省第一人民医院 技术支持:重庆聚合科技有限公司 地址:云南省昆明市西山区金碧路157号